"Histamine H2 Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that selectively bind to but do not activate histamine H2 receptors, thereby blocking the actions of histamine. Their clinically most important action is the inhibition of acid secretion in the treatment of gastrointestinal ulcers. Smooth muscle may also be affected. Some drugs in this class have strong effects in the central nervous system, but these actions are not well understood.
| Descriptor ID |
D006635
|
| MeSH Number(s) |
D27.505.519.625.375.425.425 D27.505.696.577.375.425.425
|
| Concept/Terms |
Histamine H2 Antagonists- Histamine H2 Antagonists
- Receptor Blockaders, H2
- Blockaders, Histamine H2 Receptor
- Histamine H2 Receptor Blockaders
- Histamine H2 Blockers
- Blockers, Histamine H2
- H2 Blockers, Histamine
- Receptor Antagonists, Histamine H2
- Histamine H2 Receptor Antagonists
- Antagonists, Histamine H2
- H2 Antagonists, Histamine
- H2 Receptor Blockaders
- Blockaders, H2 Receptor
- Antihistaminics, H2
- H2 Antihistaminics
|
Below are MeSH descriptors whose meaning is more general than "Histamine H2 Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Histamine H2 Antagonists".
This graph shows the total number of publications written about "Histamine H2 Antagonists" by people in this website by year, and whether "Histamine H2 Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Histamine H2 Antagonists" by people in Profiles.
-
Association Between Preadmission Acid Suppressive Medication Exposure and Severity of Illness in Patients Hospitalized With COVID-19. Gastroenterology. 2021 Mar; 160(4):1417-1422.e14.
-
Peptic ulcer disease. Am Fam Physician. 2007 Oct 01; 76(7):1005-12.
-
Inhibition of epidermal growth factor receptor activation enhances in vivo histamine-stimulated gastric acid secretion in the rat. Dig Dis Sci. 2006 Feb; 51(2):274-81.
-
The efficacy of omeprazole twice daily with supplemental H2 blockade at bedtime in the suppression of nocturnal oesophageal and gastric acidity. Aliment Pharmacol Ther. 2003 Jun 15; 17(12):1553-8.
-
Sleep-related gastro-oesophageal reflux: provocation with a late evening meal and treatment with acid suppression. Aliment Pharmacol Ther. 1998 Oct; 12(10):1033-8.
-
Patterns of 24-hour oesophageal acid exposure after acute withdrawal of acid suppression. Aliment Pharmacol Ther. 1995 Oct; 9(5):571-4.
-
Gastritis with valproate therapy. Arch Neurol. 1988 Aug; 45(8):903-5.